Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Axatilimab (SNDX-6352) in Idiopathic pulmonary fibrosis. The expected timing is based on the latest available company guidance and may change.
MAXPIRe trial. Initiate trial in YE 2023. 3/25/24- Enrollment ongoing. 1/13/25- Enrollment completion in 2025 w/ topline data in 2026. 11/03/25:- MAXPIRe Ph2 IPF trial enrollment expected complete by end 2025; topline data anticipated in H2 2026. 02/26/26:- MAXPIRe Ph2 IPF trial completed enrollment in Q1 2026; topline data expected in Q4 2026. 04/30/26:- MAXPIRe Ph2 IPF topline axatilimab data remains expected in Q4 2026 after Q1 2026 enrollment completion. 08/04/26:- MAXPIRe Ph2 IPF topline data reiterated for Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.